文献速递免疫规划

轮状病毒疫苗在≥8月龄人群中的安全性:美国VAERS 2006-2019分析

Safety profile of rotavirus vaccines among individuals aged ≥8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019.
PubMed 文献 · Vaccine · 2020-11-29

基于美国疫苗不良事件报告系统(VAERS)2006-2019年数据,分析≥8月龄人群接种轮状病毒疫苗后的报告。共344份报告,32份(9.3%)为严重报告;未发现预期外不良事件,RV1与RV5安全性无差异。建议医务人员遵循ACIP推荐程序,较大年龄个体应防范接种儿童带来的潜在二次暴露。

要点

  • ≥8月龄人群轮状病毒疫苗报告以不适宜程序和不适宜年龄为主,严重报告占9.3%。
  • ≥6岁人群60%报告为潜在间接暴露,提示需防范接种儿童的二次暴露。
  • 未发现预期外不良事件,RV1与RV5安全性无差异。

核心结论

  • 在≥8月龄人群中未发现轮状病毒疫苗的预期外不良事件,RV1与RV5安全性无差异。

研究设计与样本

  • 对美国VAERS 2006-2019年≥8月龄人群的轮状病毒疫苗报告进行回顾性分析,共344份报告,按年龄(≥8月龄-≤5岁和≥6岁)、疫苗品牌、不良事件、严重性和暴露方式分类。

主要发现

  • 344份报告中32份(9.3%)为严重报告。
  • ≥8月龄-≤5岁组309份报告中307份(99%)为儿童直接接种。
  • ≥6岁组35份报告中21份(60%)为对接种儿童的潜在间接暴露。
  • 年轻组常见不良事件为不适宜用药程序104份(34%)和不适宜年龄用药45份(15%)。
  • ≥6岁组常见不良事件为意外暴露9份(26%)和眼刺激7份(20%)。

关键数值与推荐

  • ACIP推荐RV5或RV1免疫程序在14周6天前开始,并在8月0天前完成。

临床怎么用

  • 医务人员应遵循ACIP推荐的轮状病毒疫苗接种程序。
  • 较大年龄个体应采取必要预防措施,避免因接种儿童导致潜在二次暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2006 and 2008, two live, oral rotavirus vaccines, RotaTeq (RV5) and Rotarix (RV1), were introduced into the routine immunization program in the United States. A previous rotavirus vaccine, RotaShield, was associated with an increased risk of intussusception, with data suggesting an age-dependent variation in risk. Advisory Committee on Immunization Practices (ACIP) currently recommends that RV5 or RV1 immunization be initiated by age 14 weeks and 6 days and completed by 8 months 0 days. METHODS: We searched for U.S. VAERS reports of RV5, RV1, or unknown rotavirus vaccine brand among individuals aged ≥8 months. We analyzed reports by 2 age groups (individuals aged ≥8 months-≤5 years and ≥6 years), vaccine brand name, adverse event (AE) reported, classification of seriousness (death, non-death serious, and non-serious) and mode of exposure (direct vs. indirect exposure). For serious reports we reviewed available medical records and assigned a primary diagnosis. RESULTS: VAERS received a total of 344 U.S. reports following rotavirus vaccination among individuals ≥8 months of age, 32 (9.3%) were serious. In the younger age-group, 307 (99%) of 309 reports followed direct vaccination of the child. In contrast, in individuals aged ≥6 years, 21 (60%) of 35 reports were via potential indirect exposure to a vaccinated child. The frequently reported AEs in the younger age-group were inappropriate schedule of drug administration 104 (34%) and drug administered to patient of inappropriate age 45 (15%); in the older group these were accidental exposure 9 (26%) and eye irritation 7 (20%). No difference in the safety profile was observed between RV1 and RV5. CONCLUSIONS: We did not identify any unexpected AEs for RV vaccines among individuals aged ≥8 months. Health care providers should adhere to the ACIP recommended schedule and older individuals should apply necessary precautions to prevent potential secondary exposure from vaccinated children.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haber P, Tate J, Marquez PL, et al. Safety profile of rotavirus vaccines among individuals aged ≥8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019. Vaccine. 2020. PMID: 33267969. doi:10.1016/j.vaccine.2020.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。